Study summary
A newer BTK pill cut the risk of progression by 80% as first treatment
80%lower risk of progression or death than chemo-immunotherapy
What was tested
Pirtobrutinib, a non-covalent BTK inhibitor that works even against some resistance mutations, against bendamustine-rituximab chemo-immunotherapy, for untreated CLL without 17p deletion.
What they found
- Risk of progression or death was about 80% lower (hazard ratio 0.199).
- Early survival data also favored pirtobrutinib (hazard ratio 0.257).
What it means
Moves pirtobrutinib from a later-line option to first treatment.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.